SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is facing a volatile reaction as investors weigh a strong earnings beat against disappointing forward guidance and the unexpected departure of co-founder Reed Hastings from the board. The community remains deeply divided, with some traders capitalizing on the post-earnings sell-off to hunt for a dip, while others are bracing for further downside amid concerns over slowing growth and shifting consumer sentiment.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple (XRP) is capturing investor attention as it trades around key resistance levels, with the community closely tracking potential legislative progress on the Clarity Act. While sentiment remains divided between long-term holders anticipating institutional adoption through real-world utility and skeptics frustrated by sluggish price action, the discourse is dominated by debates over its future role in global payment infrastructure versus its perceived underperformance compared to other major crypto assets.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing significant attention as it tests key resistance levels, with the community closely tracking its potential to flip historical technical hurdles into support amid strengthening institutional interest. Investors are actively debating the impact of upcoming regulatory clarity and shifting macro conditions, viewing current price action as a critical consolidation phase ahead of potential momentum.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as traders speculate on a potential breakout driven by nearing energization milestones at its Sweetwater facility and the high anticipation of a major AI infrastructure deal. The community is actively debating the company's competitive standing against peers like NBIS, weighing the impact of share dilution against the massive value of its secured power capacity and AI compute expansion.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is experiencing heightened community interest as investors actively track its price action around key technical levels and discuss the potential for a short squeeze driven by large-scale short positions. Bullish sentiment remains focused on management's strategy to bolster cash reserves and develop new digital product offerings like "Power Packs," while ongoing debates persist regarding the influence of market makers and institutional trading tactics.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing high volatility as the community reacts to rumors of a potential executive order regarding psychedelic research. While some investors are bullish on the company's supply chain and sector positioning, others are expressing frustration over extreme price swings and concerns regarding historical share dilution.

Daddy Darth Vader

The $DARTH community is currently embroiled in an active rivalry with $MAULCOIN and a newly launched $SIDIOUS, leading to intense debates over loyalty and market strategy. Investors are closely monitoring liquidity, potential token burns, and leadership transparency as they trade between these competing projects.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXTI is currently experiencing intense volatility fueled by massive retail FOMO, speculative options flow, and conflicting institutional reports regarding its role as a key supplier for AI infrastructure. The community remains sharply divided between bulls betting on indium phosphide bottlenecks and bears citing extreme valuation concerns, insider selling, and potential dilution risks ahead of upcoming earnings.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace is trending following the successful launch of its Alpha rocket and an optimistic price target update from Roth Capital, fueling investor enthusiasm for its lunar and defense programs. The community is actively discussing the stock's potential for a broader valuation re-rating, contrasting its diversified aerospace software strategy against peers while weighing momentum against short-term volatility.

Operates as a holding company with interest in providing social shopping platform solutions

WeShop Holdings Ltd - Ordinary Shares - Class A

WeShop Holdings Limited

WeShop Holdings Limited is currently experiencing extreme volatility driven by a classic low-float short squeeze, with the community actively comparing its rapid price action to recent market runners like $BIRD and $MYSE. While bullish investors are aggressively pushing for higher price targets and highlighting massive volume, skeptics are warning that this is a high-risk pump-and-dump scheme prone to sudden reversals and frequent trading halts.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Incannex stated that its financial position is strong, with about $75 million in cash and no debt on its books.</li><li>The company stated that as of Dec. 31, 2025, it had approximately $18.5 million available for repurchases under the share repurchase program.</li><li>Incannex is currently undertaking trials of IHX-42X and PSX-001 for the treatment of Obstructive Sleep Apnea and Generalized Anxiety Disorder, respectively.</li></ul>Incannex Healthcare Inc. (IXHL) on Friday announced that it has reactivated its share repurchase program, saying that it has been active over the past two trading days.The company cited a “significant disconnect” between its market capitalization and the underlying financial strength, as well as the progress it has achieved across its clinical programs.Incannex stated that it intends to continue utilizing the share repurchase program “opportunistically.”<a href="https://stocktwits.com/symbol/IXHL">Incannex Healthcare</a> shares gained more than 6% in Friday’s opening trade before paring some of the gains. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Incannex Touts Financial Strength</h2>The company stated that its financial position is strong, with about $75 million in cash and no debt on its books.“We are in a strong financial position to execute on our clinical development strategy while maintaining the flexibility to allocate capital in a disciplined and strategic manner,” said Incannex CEO Joel Latham.Incannex is currently undertaking trials of IHX-42X and PSX-001, its treatments for Obstructive Sleep Apnea (OSA) and Generalized Anxiety Disorder (GAD), respectively.The company stated that as of Dec. 31, 2025, it had approximately $18.5 million available for repurchases under the share repurchase program.<h2 class="st-heading-2">Incannex’s Obstructive Sleep Apnea Trial</h2>Incannex stated that Phase 2 clinical trials showed that IHX-42X’s lowest dose is the most effective for addressing OSA, reducing the Apnea-Hypopnea Index (AHI) by 51% compared with baseline. Incannex stated that one in four participants reported an 80% reduction in AHI.AHI is a key metric for gauging the severity of OSA, measuring how many apneas (complete breathing pauses) and hypopneas (partial airway blockages) occur per hour of sleep.The company said a global Phase 2/3 trial is currently underway to assess the efficacy and safety of IHL-42X.<h2 class="st-heading-2">Incannex’s Generalized Anxiety Disorder Trial</h2>The company noted that in the Phase 2 clinical trial of PSX-001 for the treatment of Generalized Anxiety Disorder (GAD), 44% of the participants who received the treatment reported a clinically meaningful or at least a 50% reduction in their anxiety scores.<a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> is down 68% year-to-date and 84% over the past 12 months. AdvisorShares Psychedelics ETF (PSIL) is up 35% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-gctk-stock-soaring-today/cZ3HcZMRIlU">GCTK Stock Is Soaring Pre-Market Today — What Is Fueling The Surge?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Incannex Healthcare Inc. logo is seen on a smartphone and in the background.

Incannex Reactivates Share Repurchase Program, Cites ‘Significant Disconnect’ Between Its Market Cap And Financial Strength

Incannex Healthcare - The company stated that it intends to continue utilizing the share repurchase program “opportunistically.”

IXHL Stock Gains As Incannex Reactivates Share Repurchase Program

Equity

The company stated that it intends to continue utilizing the share repurchase program “opportunistically.”

Incannex Healthcare Stock Falls 35% Over Announcement Of IHL-42X Development Plan, Stock Offering

(RTTNews) - Shares of Incannex Healthcare Inc. (IXHL) are falling about 35 percent on Thursday morning trading following the announcement of an enhanced clinical development strategy for IHL-42X, its...

<ul class="summary-bullets"><li>If the warrants are fully exercised for cash, Incannex could receive up to an additional $13 million.</li><li>The company said the funds should support completion of the Phase 2 DReAMzz study for its IHL-42X program.</li><li>Phase 2 RePOSA trial showed that IHL-42X delivered statistically significant improvements, reducing breathing interruptions during sleep, preserved REM sleep, and showed no serious safety concerns.</li></ul>Shares of Incannex Healthcare Inc (IXHL) fell 35% on Thursday, after the company announced the pricing of its $10 million private placement. The company also shared that the Phase 3 development of its oral drug candidate for obstructive sleep apnea is not expected to begin until the second half of 2027.The company plans to issue 2 million shares of common stock, or equivalents, along with warrants to purchase up to another 2 million shares at a combined price of $5.00 per share and accompanying warrant. IHXL shares closed at $5.97 in the previous session.&nbsp;Incannex announced that it has ceased using its at-the-market (ATM) facility and has no plans to use it again.If the warrants are fully exercised for cash, Incannex could receive up to an additional $13 million, bringing total potential proceeds to about $23 million. The company said the funds should support completion of the Phase 2 DReAMzz study for its IHL-42X program, while existing cash will remain available for planned Phase 3 development expected to begin in the second half of 2027.<h2 class="st-heading-2">Incannex’s Plan Ahead</h2>The firm said it has updated the clinical development strategy for its oral drug candidate IHL-42X, to treat obstructive sleep apnea, after positive results from its Phase 2 study. The therapy has also received Fast Track designation from the U.S. Food and Drug Administration.The company intends to run a Phase 2 crossover study, known as DReAMzz, to optimize the drug’s dosage before advancing to a streamlined Phase 3 program. The study aims to improve dosing precision and build stronger clinical data ahead of late-stage development.Results from the Phase 2 RePOSA trial showed that IHL-42X delivered statistically significant improvements. The treatment reduced breathing interruptions during sleep, preserved REM sleep, and showed no serious safety concerns.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp selloff, retail sentiment for <a href="https://stocktwits.com/symbol/IXHL">IXHL</a> on Stocktwits turned ‘extremely bullish,’ amid ‘extremely high’ message volumes.One user said that while the financing itself isn’t too negative, management’s communication regarding the delayed Phase 3 trial has been poor.<stembedurl>https://stocktwits.com/pavaaan/message/647327564</stembedurl>Another user said the offering “looks worse than it actually is.”<stembedurl>https://stocktwits.com/SurfyKnagg/message/647333529</stembedurl>Year-to-date, the stock has slumped 66%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did IXHL Stock Slump 35% Today?

The company priced its private placement at $5 per share, below its previous closing price of $5.97, and said the proceeds would be used for its Phase 3 treatment for sleep apnea, which is expected to begin in the second half of 2027.

<ul class="summary-bullets"><li>To support compliance, Incannex implemented a 1-for-30 reverse stock split on Feb. 26, reducing the number of outstanding shares from 358 million to about 11.9 million.</li><li>Interest has also been driven by regulatory progress for the company’s sleep apnea drug, which received Fast Track designation from the FDA in December.</li><li>Incannex plans to advance the sleep apnea therapy toward late-stage development this year.</li></ul>Shares of Incannex Healthcare (IXHL) surged to their strongest session in five months on Wednesday as investors looked ahead to potential Nasdaq compliance and upcoming regulatory discussions for the company’s sleep apnea drug.<a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> jumped over 19% on Wednesday to close at $5.97, marking the company’s third straight session of gains.<h2 class="st-heading-2">Nasdaq Compliance Timeline</h2>Incannex said in October that Nasdaq had granted it a 180-day extension to regain compliance with the exchange’s minimum bid price requirement, giving the company until April 20 to meet the rule. Under Nasdaq guidelines, companies must maintain a closing bid price of at least $1 for at least 10 consecutive trading days to regain compliance.As part of its efforts to regain compliance, Incannex implemented a 1-for-30&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-ixhl-stock-tank-over-today/cZRy4khRIGO">reverse stock split</a> effective Feb. 26, with trading on a split-adjusted basis beginning the following day. The move reduced the company’s outstanding share count from 358 million to 11.9 million shares, while lifting its per-share price.<h2 class="st-heading-2">Regulatory Catalyst For Sleep Apnea Drug</h2>Investor interest has also been supported by regulatory momentum for the company’s lead obstructive sleep apnea therapy, IHL-42X, which received&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/incannex-healthcare-stock-soars-15-after-fda-fast-tracks-obstructive-sleep-apnea-drug/cLIXxacRE1t">Fast Track designation</a> from the U.S. Food and Drug Administration in December.The designation followed positive results from the company’s Phase 2 RePOSA study, which showed the therapy significantly reduced breathing interruptions during sleep, with reductions of up to 83% in some patients, along with positive patient feedback and a favorable safety profile.Fast Track status allows for more frequent meetings with the FDA, eligibility for rolling review of a future drug application, and the possibility of accelerated approval or priority review if the therapy meets relevant criteria. Incannex expects to receive written feedback from the FDA on its Phase 2 data package and clinical development strategy, which will help determine the path toward late-stage clinical development.<h2 class="st-heading-2">Clinical Pipeline Backed By Solid Cash Runway</h2>Incannex has also highlighted a strengthened financial position as it advances its clinical pipeline. In January, the company said it entered 2026 with more than $70 million in cash, providing an operating runway well into 2027.During 2025, the company reported two positive Phase 2 clinical readouts, including results for its sleep apnea program and a separate psilocybin-based therapy for generalized anxiety disorder. Incannex said it plans to advance the sleep apnea program toward later-stage development, while continuing regulatory planning for the anxiety treatment this year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IXHL was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ixhl_ss_png_a8ed2aecde.webp" alt="ixhl ss.png" width="973" height="141"><figcaption>IXHL sentiment and message volume as of March 12 | Source: Stocktwits</figcaption></figure>One user <a href="https://stocktwits.com/Santa_Claus_Trades/message/647252179">said</a> they were continuing to hold their position and planned to add shares ahead of the Nasdaq compliance window, noting the stock often moves higher heading into potential news, including a possible announcement of an end-of-Phase 2 meeting.<stembedurl>https://stocktwits.com/Santa_Claus_Trades/message/647252179</stembedurl>Another user <a href="https://stocktwits.com/Nawaf643/message/647272427">said</a>, “Tomorrow is Day 10 above $1 — compliance locked. The real show may start after that. Be ready… big news could start dropping as soon as tomorrow.”<stembedurl>https://stocktwits.com/Nawaf643/message/647272427</stembedurl>IXHL stock has declined 73% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms

IXHL Stock - Investors are watching the company’s Nasdaq compliance timeline after it received a 180-day extension until April 20 to meet the $1 minimum bid rule.

Investors are watching the company’s Nasdaq compliance timeline after it received a 180-day extension until April 20 to meet the $1 minimum bid rule.

Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Update

Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the target of a large drop in short interest in February. As of February 27th, there was short interest totaling 842,808 shares, a drop of...

Incannex Healthcare (NASDAQ:IXHL) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised Incannex Healthcare to a "sell" rating in a report on Saturday...

Incannex Healthcare (NASDAQ:IXHL) Stock Price Down 11% - What's Next?

Incannex Healthcare (NASDAQ:IXHL) Stock Price Down 11% - Here's Why...

<ul class="summary-bullets"><li>The reverse split will consolidate every 30 existing shares into one new share.</li><li>The move is intended to help the company comply with Nasdaq’s minimum bid price requirements.</li><li>After the split, the company’s outstanding shares will decrease from roughly 358.3 million to about 11.94 million.</li></ul>Incannex Healthcare Inc. (IXHL) announced on Wednesday that its board of directors has approved a 1-for-30 reverse stock split, which was previously approved by shareholders at a special meeting on May 27, 2025.The reverse split is set to take legal effect at 4:01 p.m. ET on Feb. 26, 2026.<h2 class="st-heading-2">Purpose And Impact Of The Split</h2>Following this adjustment, Incannex Healthcare common shares will begin trading on The Nasdaq Capital Market under a new CUSIP number, 45333F 208, on February 27, while retaining the ticker symbol ‘IXHL’.The reverse split will consolidate every 30 existing shares into one new share, aiming to raise the per-share market price. The move is intended to help the company comply with Nasdaq’s minimum bid price requirements and maintain continued listing eligibility.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/IXHL">Incannex stock</a> tumbled over 32% on Wednesday morning. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Share Structure And Equity Adjustments</h2>Incannex said that&nbsp;no fractional shares will be issued, and shareholders entitled to fractional amounts will receive an additional share to round up to a whole unit.&nbsp;After the split, the company’s outstanding shares will decrease from roughly 358.3 million to about 11.94 million, although the total number of authorized shares will remain unchanged. Existing equity awards and stock incentive plans will see proportional adjustments in both share numbers and exercise prices to reflect the split.&nbsp;In January, Incannex said it is entering 2026 with over $70 million in cash, following a $12.5 million private placement financing and the elimination of legacy Series A warrants. The company also authorized a $20 million share repurchase program.IXHL stock has declined by over 87% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-q4-earnings-today-retail-says-pressure-is-worse-this-time/cZRy3JBRIG4">Nvidia Q4 Earnings Today – Retail Says 'Pressure Is Worse This Time’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did IXHL Stock Tank Over 32% Today? 

The company’s board approved a 1-for-30 reverse stock split, effective on February 26. The move is intended to help the company comply with Nasdaq’s minimum bid price requirements.

The company’s board approved a 1-for-30 reverse stock split, effective on February 26. 


Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Large Growth in Short Interest

Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the target of a significant increase in short interest in January. As of January 30th, there was short interest totaling 21,688,567...

Incannex Healthcare (NASDAQ:IXHL) Announces Quarterly Earnings Results

Incannex Healthcare (NASDAQ:IXHL - Get Free Report) issued its earnings results on Friday. The company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02...

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

IXHL
Incannex Healthcare Limited - ADR

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IXHL News

IXHLIncannex Healthcare Limited - ADR